Sign Up Today and Learn More About Galera Therapeutics Stock
Invest in or calculate the value of your shares in Galera Therapeutics or other pre-IPO companies through EquityZen's platform.
Galera Therapeutics Stock
Therapeutic agents for preventing damage due to radiation treatment of cancer
About Galera Therapeutics Stock
Founded
2009
Headquarters
Malvern, PA, US
Total Funding
149M
Industries
Software, Artificial Intelligence, Data and Analytics
Galera Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing novel therapeutics targeting oxygen metabolic pathways with the potential to transform how radiation therapy is used in patients with cancer. Galera’s lead product candidate is GC4419, a highly selective and potent small molecule superoxide dismutase enzyme mimetic that rapidly converts superoxide to hydrogen peroxide and oxygen. GC4419 achieved positive results in a Phase 2b clinical trial, which demonstrated its ability to reduce the incidence and duration of radiation-induced severe oral mucositis in patients with head and neck cancer, its lead indication. The U.S. Food and Drug Administration granted Fast Track and Breakthrough Therapy designations to GC4419.
Galera Therapeutics Management
Leadership team at Galera Therapeutics
President, Chief Executive Officer & Board of Directors
Mel Sorensen
Co-Founder & Chief Scientific Officer
Dennis P. Riley
Join now and verify your accreditation status to gain access to:
- Galera Therapeutics current valuation
- Galera Therapeutics stock price
- Available deals in Galera Therapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Galera Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Galera Therapeutics through EquityZen funds. These investments are made available by existing Galera Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Galera Therapeutics stock?
Shareholders can sell their Galera Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
